NICE to review its decision making processes

pharmafile | July 22, 2019 | News story | Sales and Marketing Cost, NHS, NICE, UK, britain, pharma 

Britain’s cost-effectiveness body NICE has said it will review the methods it uses to develop guidance on drugs, medical devices, and diagnostics.

The review will see NICE look at the processes through which its decisions are made. This will include looking at the way data analytics and real-world evidence can be used in the decision making process. Proposals will be presented for public consultation in the summer of 2020.  

Sir Andrew Dillon, chief executive of NICE, commented: “This update is part of the regular review and refresh of our methods to ensure that they are robust and up-to-date.

“NICE is undertaking this review at a time of unprecedented change in the healthcare system, where developments such as personalised medicine, digitalisation of health, and use of cell and gene therapy, mean products are becoming ever more challenging to evaluate.

“Keeping NICE’s methods up to date is an important contribution to managing these changes. The expanded Accelerated Access Collaboration, and the development of NHS England’s commercial framework are other important elements.

“NICE encourages people who are interested in the methods and process review to register an interest on the NICE website to ensure they receive regular updates on this work.”

Other topics scheduled for consideration include: the ways in which quality of life is factored in to economic analyses and issues related specifically to technology.

Louis Goss

Related Content

NICE approves first treatment for obstructive HCM for NHS use

The National Institute for Health and Care Excellence (NICE) has announced that it has approved …

NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks

The National Institute for Health and Care Excellence (NICE) has announced that it has recommended …


NHS given guidance on offering genetic testing to stroke patients

The NHS has been given draft guidance on offering gene tests to patients who have …

Latest content